Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.

Journal of thrombosis and haemostasis : JTH - 1 Dec 2007

Brandt J T, Close S L, Iturria S J, Payne C D, Farid N A, Ernest C S, Lachno D R, Salazar D, Winters K J

Abstract excerpt

BACKGROUND: Thienopyridines are metabolized to active metabolites that irreversibly inhibit the platelet P2Y(12) adenosine diphosphate receptor. The pharmacodynamic response to clopidogrel is more variable than the response to prasugrel, but the reasons for variation in response to clopidogrel are not well characterized. OBJECTIVE: To determine the relationship between genetic variation in cytochrome P450 (CYP)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cross-Over Studies
Share to Platelet Aggregation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Prasugrel Hydrochloride

Share to Prodrugs

Share to Receptors, Purinergic P2

Share to Receptors, Purinergic P2Y12

Share to Thiophenes

Share to Ticlopidine

Source

Identifiers

PMID: 17900275
DOI: 10.1111/j.1538-7836.2007.02775.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.PMID 17900275Read ↗

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.Semantic proximity Read ↗

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.Semantic proximity Read ↗

Pharmacogenetics of clopidogrel.Semantic proximity Read ↗

Cytochrome p-450 polymorphisms and response to clopidogrel.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.Semantic proximity Read ↗

The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.Semantic proximity Read ↗

Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.Semantic proximity Read ↗

Genetic Determinants of Response to P2Y12 Inhibitors and Clinical Implications.Semantic proximity Read ↗

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).Semantic proximity Read ↗

Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.Semantic proximity Read ↗

Clopidogrel PharmacogeneticsSemantic proximity Read ↗

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.